Peripheral Neuropathy News and Research RSS Feed - Peripheral Neuropathy News and Research

Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
FDA approves safety labeling changes for fluoroquinolone antibiotics

FDA approves safety labeling changes for fluoroquinolone antibiotics

The U.S. Food and Drug Administration today approved safety labeling changes for a class of antibiotics, called fluoroquinolones, to enhance warnings about their association with disabling and potentially permanent side effects and to limit their use in patients with less serious bacterial infections. [More]
Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Five-year survival data published online today in Blood, the Journal of the American Society of Hematology, suggest that the targeted therapy brentuximab vedotin may have cured some Hodgkin lymphoma patients whose disease has persisted despite receiving previous therapies. [More]
Argentine Tango dance holds potential to reduce fall risk among cancer survivors with neuropathy

Argentine Tango dance holds potential to reduce fall risk among cancer survivors with neuropathy

Dance as a form of therapy - specifically Argentine Tango -- has the potential to significantly improve balance and reduce falls risk among cancer patients experiencing peripheral neuropathy, according to new research conducted by a multidisciplinary research team at The Ohio State University. [More]
Oncologists to present latest research findings at ASCO annual meeting

Oncologists to present latest research findings at ASCO annual meeting

Oncologists from NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine will discuss their latest research findings at the American Society for Clinical Oncology annual meeting, June 3-7 in Chicago. [More]
NR supplements can reduce diabetes-related complications in mice

NR supplements can reduce diabetes-related complications in mice

A naturally occurring vitamin, nicotinamide riboside (NR), can lower blood sugar levels, reduce fatty liver, and prevent peripheral nerve damage in mouse models of prediabetes and type 2 diabetes (T2D), according to a new study by researchers at the University of Iowa and the Iowa City VA Health Care System. [More]
Microvascular disease burden tied to CVD outcomes in diabetic patients

Microvascular disease burden tied to CVD outcomes in diabetic patients

The risk of cardiovascular disease events in patients with Type 2 diabetes rises in line with their cumulative burden of microvascular disease, research shows. [More]
Multivitamin use prior to diagnosis may reduce effects of CIPN in breast cancer survivors

Multivitamin use prior to diagnosis may reduce effects of CIPN in breast cancer survivors

Researchers at Roswell Park Cancer Institute, in collaboration with investigators from the cooperative group SWOG, have found that use of multivitamins prior to diagnosis may reduce the risk of neuropathy in breast cancer patients treated with the class of drugs known as taxanes. The team will present their findings at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans. [More]
Small fibre neuropathy defies 'dying-back' nerve process

Small fibre neuropathy defies 'dying-back' nerve process

Neuronal degradation in patients with small fibre neuropathy is not dependent on nerve fibre length, study findings suggest. [More]
Scientists discover underlying mechanisms of nerve damage

Scientists discover underlying mechanisms of nerve damage

Recent research by Sandra Rieger, Ph.D., of the MDI Biological Laboratory identifying the underlying mechanisms of peripheral neuropathy, or nerve damage, has raised the prospect that drug therapies can be developed for the treatment of this condition, which causes pain, numbness and/or tingling in the hands and feet. The research was published March 28 in the Proceedings of the National Academy of Sciences. [More]
Neurofeedback decreases pain, increases quality of life in patients with neuropathic pain

Neurofeedback decreases pain, increases quality of life in patients with neuropathic pain

A new study from The University of Texas MD Anderson Cancer Center evaluating the use of neurofeedback found a decrease in the experience of chronic pain and increase quality of life in patients with neuropathic pain. [More]
MDI Biological Laboratory scientist identifies potential drug therapy to reverse peripheral nerve damage

MDI Biological Laboratory scientist identifies potential drug therapy to reverse peripheral nerve damage

The Mount Desert Island Biological Laboratory has announced that assistant professor Sandra Rieger, Ph.D., has identified two drugs that could potentially be used to reverse peripheral nerve damage, or peripheral neuropathy, resulting from chemotherapy treatment for ovarian, breast, lung, pancreas and other cancers. The drugs also have potential applications for the treatment of peripheral nerve damage caused by diabetes, traumatic injuries and other conditions. [More]
RegeneRx Biopharmaceuticals announces completion of enrollment for Phase 2b/3 dry eye trial in U.S.

RegeneRx Biopharmaceuticals announces completion of enrollment for Phase 2b/3 dry eye trial in U.S.

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture with G-treeBNT, ReGenTree LLC, has completed enrollment of its Phase 2b/3 dry eye trial in the U.S. [More]
Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai Inc. announced today that the U.S. Food and Drug Administration approved Halaven (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. [More]
Halaven (eribulin mesylate) approved for treatment of liposarcoma

Halaven (eribulin mesylate) approved for treatment of liposarcoma

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. [More]
Araim Pharmaceuticals forms new strategic collaboration with Vault Bioventures to market novel peptides

Araim Pharmaceuticals forms new strategic collaboration with Vault Bioventures to market novel peptides

Araim Pharmaceuticals has formed a long-term strategic partnership with Vault Bioventures to facilitate the advancement to market of its novel peptide library which targets devastating injuries and chronic diseases underserved by current therapies. [More]
Nuvo Research announces topline results from WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo Research announces topline results from WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo Research Inc., a life sciences company with growing revenues and a diverse portfolio of topical products, today announced the results of its investigational Phase 2 clinical trial of WF10 (Trial) for the treatment of allergic rhinitis. [More]
Role for carfilzomib in relapsed, refractory multiple myeloma treatment

Role for carfilzomib in relapsed, refractory multiple myeloma treatment

Carfilzomib significantly improves outcomes in previously treated patients with relapsed or refractory multiple myeloma, shows a head-to-head comparison with bortezomib. [More]
Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma. [More]
FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. [More]
Ninlaro (ixazomib) approved to treat people with multiple myeloma

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy. [More]
Advertisement
Advertisement